Recursion (NASDAQ: RXRX) director sells 170,000 shares in open market

Rhea-AI Filing Summary

Recursion Pharmaceuticals director Blake Borgeson sold shares in an open-market transaction. On 2026-03-03, he sold 170,000 shares of Class A common stock at an average price of $3.46 per share. After this sale, he directly owns 6,259,863 shares of the company’s Class A common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borgeson Blake

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/03/2026		S		170,000	D	$3.46	6,259,863	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Recursion Pharmaceuticals (RXRX) disclose for Blake Borgeson?

Recursion Pharmaceuticals reported that director Blake Borgeson sold 170,000 shares of Class A common stock. The transaction was an open-market sale at an average price of $3.46 per share on 2026-03-03, according to the Form 4 data.

How many Recursion Pharmaceuticals (RXRX) shares did Blake Borgeson sell and at what price?

Blake Borgeson sold 170,000 shares of Recursion Pharmaceuticals Class A common stock. The reported average sale price was $3.46 per share, reflecting an open-market transaction completed on 2026-03-03, as disclosed in the insider trading report.

How many Recursion Pharmaceuticals (RXRX) shares does Blake Borgeson own after the sale?

After the reported sale, Blake Borgeson directly owns 6,259,863 shares of Recursion Pharmaceuticals Class A common stock. This post-transaction holding reflects his remaining direct ownership following the 170,000-share open-market sale on 2026-03-03.

Was the Blake Borgeson Recursion Pharmaceuticals (RXRX) trade a buy or a sell?

The Blake Borgeson transaction in Recursion Pharmaceuticals stock was a sell. Form 4 data classifies it as an open-market sale of 170,000 Class A common shares at an average price of $3.46 per share on 2026-03-03.

What type of security did Blake Borgeson trade in Recursion Pharmaceuticals (RXRX)?

Blake Borgeson traded Recursion Pharmaceuticals Class A common stock. The filing shows a non-derivative, open-market sale of 170,000 Class A shares at an average price of $3.46 per share, executed on 2026-03-03.